Compare Carvana Co (CVNA) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs Merck & Co., Inc. — how do they compare? Carvana Co trades at $64.08 (market cap $69.55B), while Merck & Co., Inc. trades at $144.83 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 5.1× Carvana Co's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Carvana Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and Merck & Co., Inc. for 98 Days on average.
| CVNA | MRK | |
|---|---|---|
Market Cap | $69.55B | $351.28B |
Volume | 7,671,750 | 7,969,665 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $156.43 |
52-Week Low | $56.27 | $82.49 |
Typical Hold Time | 28 Days | 98 Days |
Enterprise Value | $72.04B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $62.76, down 1.72% with bearish technical signals but strong fundamental momentum. The stock shows impressive revenue growth from $13.7B in 2024 to $20.3B in 2025, with net income surging to $1.4B. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.42 exceeding the $0.39 forecast. Analyst sentiment remains divided with a $84.07 consensus target, though technical indicators show selling pressure with bearish moving averages and key resistance at $64.
Carvana presents a compelling growth story with expanding profitability and operational efficiency, though high valuation multiples and significant debt levels warrant caution. The company's aggressive capacity expansion addresses demand constraints, positioning it for continued market share gains in online auto retail. However, competitive pressures and macroeconomic sensitivity to interest rates remain key risks for investors.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
